Complete remission of primary plasma cell leukemia with bortezomib, doxorubicin, and dexamethasone
Author Information
Author(s): Steven M Chan, Tracy George, Athena M Cherry, Bruno C Medeiros
Primary Institution: Stanford University School of Medicine
Hypothesis
Can a combination of bortezomib, doxorubicin, and dexamethasone achieve remission in primary plasma cell leukemia?
Conclusion
The combination of bortezomib, doxorubicin, and dexamethasone shows promise in treating primary plasma cell leukemia, leading to complete remission.
Supporting Evidence
- The patient achieved complete remission after treatment with the combination regimen.
- The regimen is currently under evaluation for multiple myeloma but has not been extensively studied for plasma cell leukemia.
- The patient experienced significant treatment-related toxicities, including peripheral neuropathy.
Takeaway
A man with a rare blood cancer got better after taking a special mix of three medicines.
Methodology
The patient received a combination of bortezomib, doxorubicin, and dexamethasone as front-line induction chemotherapy over 5 cycles.
Limitations
The study is based on a single case report, limiting generalizability.
Participant Demographics
54-year-old African-American man with no significant past medical history.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website